[{"address1": "18702 N. Creek Parkway", "address2": "Suite 100", "city": "Bothell", "state": "WA", "zip": "98011", "country": "United States", "phone": "610-321-3700", "website": "https://immunome.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.", "fullTimeEmployees": 62, "auditRisk": 7, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 12.58, "open": 12.68, "dayLow": 12.14, "dayHigh": 12.99, "regularMarketPreviousClose": 12.58, "regularMarketOpen": 12.68, "regularMarketDayLow": 12.14, "regularMarketDayHigh": 12.99, "beta": 1.853, "forwardPE": -4.7300377, "volume": 3385420, "regularMarketVolume": 3385420, "averageVolume": 869100, "averageVolume10days": 1119900, "averageDailyVolume10Day": 1119900, "bid": 12.43, "ask": 12.53, "bidSize": 200, "askSize": 200, "marketCap": 746013120, "fiftyTwoWeekLow": 5.335, "fiftyTwoWeekHigh": 30.958, "priceToSalesTrailing12Months": 58.819927, "fiftyDayAverage": 15.1868, "twoHundredDayAverage": 14.100375, "currency": "USD", "enterpriseValue": 437931712, "floatShares": 42891533, "sharesOutstanding": 59968900, "sharesShort": 6123723, "sharesShortPriorMonth": 3747870, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1021, "heldPercentInsiders": 0.17083, "heldPercentInstitutions": 0.61515, "shortRatio": 6.94, "shortPercentOfFloat": 0.108, "impliedSharesOutstanding": 59968900, "bookValue": 4.784, "priceToBook": 2.6003344, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -232028000, "trailingEps": -17.58, "forwardEps": -2.63, "enterpriseToRevenue": 34.529, "enterpriseToEbitda": -9.934, "52WeekChange": 1.3252337, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "IMNM", "underlyingSymbol": "IMNM", "shortName": "Immunome, Inc.", "longName": "Immunome, Inc.", "firstTradeDateEpochUtc": 1601645400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c2147e86-3bc9-3a00-bf6a-53fc4499717d", "messageBoardId": "finmb_108518404", "gmtOffSetMilliseconds": -14400000, "currentPrice": 12.44, "targetHighPrice": 38.0, "targetLowPrice": 27.0, "targetMeanPrice": 33.25, "targetMedianPrice": 34.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 309705984, "totalCashPerShare": 5.164, "ebitda": -44082000, "totalDebt": 1625000, "quickRatio": 10.066, "currentRatio": 10.184, "totalRevenue": 12683000, "debtToEquity": 0.569, "revenuePerShare": 0.427, "returnOnAssets": -0.15156001, "returnOnEquity": -1.54978, "freeCashflow": -18518250, "operatingCashflow": -42911000, "revenueGrowth": -0.565, "grossMargins": -1.7107899, "operatingMargins": -19.77162, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]